Company intelligence / Profile preview
GlyTherix
Sydney, Australiaglytherix.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
GlyTherix has completed a First-in-Human clinical trial dosing twelve patients with Miltuximab®, their anti-GPC1 monoclonal antibody, showing no drug-related adverse events. They are advancing to Phase Ib trials using Lutetium‑177 labeled Miltuximab® for targeted radiotherapy combined with PET imaging using Zirconium‑89 labeled Miltuximab® to select patients. The company also has an alpha-emitter program under development. Their humanized antibody candidate, Glytuzumab, is in lead optimization/preclinical stages[1][2][3][5].
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyAntibody radiopharmaceuticalCAR-T cell therapyRadiopharmaceuticals labeled with Lutetium-177 and Zirconium-89
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
SHINE TechnologiesEckert & ZieglerNusanoANSTO
Beyond the preview
Go deeper on GlyTherix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GlyTherix.